socalTECH

JUNE 23, 2015

La Jolla-based Ankasa Regenerative Therapeutics , a company developing stem-cell based products aimed at organ and tissue regrowth, repair, and healing, has raised $8.5M The funding was led by Avalon Ventures, and also included Hereaus Medical and Correlation Ventures. The startup is led by Sanford J. READ MORE>>.

Avalon 100

Avalon Organization Funding Startup 100

Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56

Avalon Invest Southern California Develop 56

socalTECH

DECEMBER 4, 2015

The funding was led by Avalon Ventures and TPG Biotech, and also included Correlation Ventures and Osage University Partners. The startup said it is developing novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types.

UCLA 100

UCLA Avalon San Diego Los Angeles 100

Xconomy

SEPTEMBER 27, 2016

Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).

Avalon 40

Avalon Funding Startup San Diego 40

Xconomy

AUGUST 17, 2016

and San Diego’s Avalon Ventures. Avelas plans to use the new funding to advance development of AVB-620, the company’s lead diagnostic agent, for use in breast cancer surgeries, CEO Carmine Stengone told me yesterday. Avalon partner Jay Lichter plans to continue serving as Avelas’ chairman, Stengone said.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. It’s a little like what Avalon is doing. We really have a development focus,” Martin told me. “We But it’s structured differently.

San Diego 40

San Diego Avalon Outsource Development Startup 40

Tech Zulu Event

DECEMBER 6, 2013

It’s something of a sci-fi fantasy scenario: Driverless cars that show up at the touch of a button. Auto-interfaces are clunky, and when a lot of these big tech companies IPO’d, a lot of them developed products that were endemic to the car industry – navigation, social graphs, etc.

Advertising 97

Advertising Startup Marketing Mobile 97

socalTECH

SEPTEMBER 19, 2008

in funding from Venrock, Avalon, and Masthead. Derrick Oien: We have a platform we develop, called ANTHEM. So do these show up as your brand or as an OEM deal with the carriers? Intercasting is backed by $17.5M What exactly are your mobile social networking applications? Derrick Oien: We are used as a white label.

Social Network 113

Social Network Anthem Mobile Java 113

Xconomy

FEBRUARY 26, 2020

About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. That day is here.

San Diego 72

San Diego Study Develop Development 72

Xconomy

JULY 19, 2016

Synthorx, the San Diego synthetic biology startup that expanded the number of DNA base pairs with two synthetic nucleotides, said today it has raised $10 million in a Series B financing round led by RA Capital Management, the Boston life sciences hedge fund. Existing investors Avalon Ventures and Correlation Ventures joined in the round.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

NOVEMBER 14, 2018

The San Diego-based company says it wants to use the proceeds to put its lead product candidate, an investigational cancer therapy that’s based on the drug interleukin-2 (IL-2), through dose escalation and expansion trials, and to develop products based on the same compound to treat autoimmune disorders.

San Diego 76

San Diego Product Develop Development 76

Xconomy

AUGUST 31, 2016

Roger Tsien, a UC San Diego scientist who shared the 2008 Nobel Prize in chemistry for research that led to the development of fluorescent proteins used to illuminate tissue and track biological processes, has died, according to a statement from the university. He compared himself to John C. Reprints | Share: UNDERWRITERS AND PARTNERS.

San Diego 72

San Diego UCSD Avalon Study 72

Xconomy

SEPTEMBER 30, 2016

Who will break free of the pack of companies developing drugs meant to prevent migraines? —Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.

Avalon 40

Avalon Thousand Oaks Study Startup 40